Abstract
Hypercalcemia is a relatively common terminal complication of malignancy. In the majority of the patients it is due to excessive bone resorption, secondary either to local destruction by metastases or by the activity of several paracrine and/ or endocrine factors. Increased renal tubular reabsorption of calcium plays a role in the aetiology and maintenance of hypercalcemia. It is due both to factors which stimulate the renal transport of calcium and to volume depletion that is frequently present in hypercalcemie patients. This explains why the administration of large amounts of fluids intravenously is often a necessary first step in the management of malignant hypercalcemia, followed by specific inhibitors of bone resorption such as the bisphosphonates.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
